CS
PRLD icon

Candriam SCA’s Prelude Therapeutics PRLD Stock Holding History

Candriam SCA’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-179,850
Closed -$1.09M – 919
2022
Q4 		$1.09M Buy
179,850
+54,231
+43% +$348K 0.01% 684
2022
Q3 		$830K Buy
+125,619
New +$847K 0.01% 753

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's PRLD Position: Q1 2023 in Review

Candriam SCA sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 179,850 shares — an estimated $1.09M sold.

Candriam SCA first reported a position in PRLD in Q3 2022 and held it in 2 quarters. The position peaked at $1.09M in Q4 2022. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

  • Candriam SCA reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Candriam SCA sold 179,850 Prelude Therapeutics shares in Q1 2023, an estimated $1.09M.
  • Candriam SCA first reported a position in Prelude Therapeutics in Q3 2022 and held it in 2 quarters.
  • Candriam SCA's Prelude Therapeutics position peaked at $1.09M in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.